Holen Sie sich die Stockscreener-App
69.85
0.23%
0.16
Handel nachbörslich:
69.85
Schlusskurs vom Vortag:
$69.69
Offen:
$69.73
24-Stunden-Volumen:
11.04M
Relative Volume:
2.24
Marktkapitalisierung:
$10.19B
Einnahmen:
$10.73M
Nettoeinkommen (Verlust:
$-455.74M
KGV:
-19.64
EPS:
-3.5569
Netto-Cashflow:
$-502.70M
1W Leistung:
+42.12%
1M Leistung:
+60.32%
6M Leistung:
+113.94%
1J Leistung:
+65.29%
1-Tages-Spanne:
$69.65
$69.91
1-Wochen-Bereich:
$69.50
$72.05
52-Wochen-Spanne:
$21.51
$72.05
Avidity Biosciences Inc Stock (RNA) Company Profile
Firmenname
Avidity Biosciences Inc
Sektor
Branche
Telefon
858-401-7900
Adresse
10578 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Vergleichen Sie RNA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RNA
Avidity Biosciences Inc
|
69.85 | 10.24B | 10.73M | -455.74M | -502.70M | -3.5569 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Avidity Biosciences Inc Stock (RNA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-17 | Eingeleitet | Roth Capital | Buy |
| 2025-07-10 | Fortgesetzt | Goldman | Buy |
| 2025-06-24 | Eingeleitet | Bernstein | Outperform |
| 2025-06-17 | Eingeleitet | Wolfe Research | Outperform |
| 2025-06-11 | Eingeleitet | Raymond James | Strong Buy |
| 2025-03-13 | Eingeleitet | Citigroup | Buy |
| 2025-03-12 | Eingeleitet | BMO Capital Markets | Outperform |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-12-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-11-26 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-09-24 | Eingeleitet | Goldman | Buy |
| 2024-08-28 | Eingeleitet | Barclays | Overweight |
| 2024-05-03 | Eingeleitet | BofA Securities | Buy |
| 2024-03-14 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-05-22 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-03-31 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-07-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2022-07-12 | Eingeleitet | Raymond James | Strong Buy |
| 2021-09-07 | Eingeleitet | Evercore ISI | Outperform |
| 2021-06-17 | Eingeleitet | Needham | Buy |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-07-07 | Eingeleitet | Cowen | Outperform |
| 2020-07-07 | Eingeleitet | Credit Suisse | Outperform |
| 2020-07-07 | Eingeleitet | SVB Leerink | Outperform |
| 2020-07-07 | Eingeleitet | Wells Fargo | Overweight |
Alle ansehen
Avidity Biosciences Inc Aktie (RNA) Neueste Nachrichten
Avidity Biosciences (RNA) Soars 42% on $12-Billion Novartis Merger - Yahoo! Finance Singapore
Applying Wyckoff theory to Avidity Biosciences Inc. stockJuly 2025 PostEarnings & Real-Time Volume Trigger Notifications - newser.com
Why Avidity Biosciences Inc. stock is popular among millennialsJuly 2025 Pullbacks & Daily Stock Momentum Reports - newser.com
Earnings visualization tools for Avidity Biosciences Inc.Weekly Trade Report & Safe Capital Growth Plans - newser.com
Exploring Avidity Biosciences (RNA) Valuation Following Recent Share Price Surge - Yahoo Finance
How Avidity Biosciences Inc. stock benefits from strong dollarJuly 2025 Patterns & Fast Gain Stock Trading Tips - newser.com
Will Avidity Biosciences Inc. stock sustain high P E ratiosJuly 2025 Analyst Calls & Weekly Stock Breakout Alerts - newser.com
How Avidity Biosciences Inc. stock compares to growth peersWeekly Profit Analysis & Technical Confirmation Alerts - newser.com
Using AI based signals to follow Avidity Biosciences Inc.Trade Analysis Report & Risk Controlled Daily Trade Plans - newser.com
10 Stocks With Easy 20-40% Gains - Insider Monkey
How Avidity Biosciences Inc. stock performs in weak economyTrade Exit Report & Free AI Powered Buy and Sell Recommendations - newser.com
Is Avidity Biosciences Inc. stock ready for breakout2025 Breakouts & Breakdowns & Technical Pattern Based Signals - newser.com
Can Avidity Biosciences Inc. stock beat market expectations this quarterForecast Cut & AI Forecast for Swing Trade Picks - newser.com
Forecasting Avidity Biosciences Inc. price range with options dataGap Down & Weekly Top Performers Watchlists - newser.com
Pharmaceutical Stocks To Keep An Eye OnOctober 28th - MarketBeat
Short interest data insights for Avidity Biosciences Inc.July 2025 Market Mood & Real-Time Volume Trigger Notifications - newser.com
What momentum shifts mean for Avidity Biosciences Inc.Portfolio Performance Report & High Return Trade Guides - newser.com
Can Avidity Biosciences Inc. stock surprise with earnings upsideWeekly Stock Recap & Precise Entry and Exit Recommendations - newser.com
Will a bounce in Avidity Biosciences Inc. offer an exitQuarterly Portfolio Report & Verified Momentum Watchlists - newser.com
Best Pharmaceutical Stocks To Follow TodayOctober 27th - MarketBeat
Avidity Biosciences (NASDAQ:RNA) Lowered to "Hold" Rating by Wolfe Research - MarketBeat
Here's Why Avidity Biosciences Stock Soared This Week (There's More to the Deal Than You Might Think) - Yahoo Finance
What Wall Street predicts for Avidity Biosciences Inc. stock priceMarket Activity Report & Free Fast Gain Swing Trade Alerts - newser.com
Will Avidity Biosciences Inc. stock deliver long term returns2025 Technical Patterns & Risk Managed Investment Signals - newser.com
Real time alert setup for Avidity Biosciences Inc. performanceMarket Activity Report & Risk Controlled Daily Trade Plans - newser.com
Using R and stats models for Avidity Biosciences Inc. forecastingTrade Analysis Report & Daily Oversold Bounce Ideas - newser.com
Novartis pays $12B for Avidity and its muscle-targeting RNA platform - Muscular Dystrophy News
Analysts Estimate Avidity Biosciences, Inc. (RNA) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
TD Cowen Downgrades Avidity Biosciences (NASDAQ:RNA) to Hold - MarketBeat
Chardan Capital Downgrades Avidity Biosciences (NASDAQ:RNA) to Hold - MarketBeat
Avidity Biosciences (NASDAQ:RNA) Stock Rating Lowered by Royal Bank Of Canada - MarketBeat
Dyne Therapeutics Stock Soars After Rival Avidity Biosciences Gets Acquired By Novartis - MSN
Avidity Biosciences (RNA) Projected to Post Earnings on Thursday - MarketBeat
Finanzdaten der Avidity Biosciences Inc-Aktie (RNA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.62%
0.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):